Alnylam Pharmaceuticals

RNA interference (RNAi) is a naturally occurring process of gene regulation that is already at work inside your body. RNAi therapeutics, which were pioneered by Alnylam, utilize this process to silence the genes that cause or contribute to disease. #ScienceCurious to learn more about #RNAi? Click here: https://bit.ly/3oR8r2l #RNAiTherapeutics #siRNA #GeneSilencing #RNA

I have so much respect and gratitude for Dr. Akshay Vaishnaw, our Chief Innovation Officer and former President, who is retiring from Alnylam Pharmaceuticals next week after 19 incredible years with the company. Akshay has played a central role in Alnylam’s history. He helped to build and lead the remarkable team that pioneered a new class of medicines, and his work led to the approval of the first five RNAi therapeutics in the world. Akshay has shaped a platform, pipeline, team, and culture that will carry us into the future as we work to write Alnylam’s next chapter and help many more patients in the years to come. On a personal level, I will miss Akshay and his wise counsel, quick wit, and amazing ability to tell the Alnylam story. Thank you, Akshay, for your extraordinary contributions!

Primary #hyperoxaluria type 1 (PH1) is an inherited disease and can affect family members in different ways. For one family with three children diagnosed with PH1, each has had a different experience. Hear from Aubrey, diagnosed with PH1,in an episode of Medical Stories airing on PBS stations. https://bit.ly/3ATSDVR

We are excited to share that the U.S. FDA has accepted our supplemental New Drug Application (sNDA) for vutrisiran, an investigational #RNAi therapeutic in development for the treatment of #ATTR-CM. https://bit.ly/412lQJn   #RNAiTherapeutics #RNAinterference #amyloidosis

Another wonderful AHA is in the books! Sharing new data from our #ATTR franchise and #hypertension program alongside fellow leaders in cardiology was truly inspiring. #RNAiTherapeutics #RNAi

It was a privilege to be part of a “Big Biotech – Where Is It Going?” panel last week at the #GalienForum2024. Thank you to Phil Sharp for facilitating a fascinating conversation on the past, present and future of our industry—and thank you to fellow panelists Jane Grogan, Ray Deshaies, Ph.D., and george yancopoulos for deepening my outlook. I walked away more convinced than ever that biotech will continue to be the source of breakthrough innovation, and that it will take experienced R&D leadership, a connected ecosystem and tenacity to deliver it. #Biotechnology #FutureOfMedicine

In case you missed it: We presented new data from our #ATTR franchise and #hypertension program at the American Heart Association Scientific Sessions 2024. Learn more: https://bit.ly/3OzzVGZ #AHA24 #RNAiTherapeutics #RNAi

Drug development is a long and perilous journey with a historically high failure rate. Advances in genomic sequencing and a more human-focused approach using genetic validation of disease targets are changing that. "Our focus on genetic validation has helped our drug candidates achieve a clinical trial success rate that's six times the industry average," says Paul Nioi, Alnylam's SVP of Discovery and Translational Research. Science curious to learn more? Read about how Alnylam and others who are embracing this approach are improving the speed and odds of success in drug development in this Nature Portfolio article (sponsored content): https://bit.ly/4hJnLbJ #RNAiTherapeutics #RNAinterference #RNAi #DrugDevelopment #genetics #genomics #biotechnology #pharmaceuticals #biopharma

At the American Heart Association Scientific Sessions 2024 (#AHA24) we presented new data on nucresiran (ALN-TTRsc04), a next-generation #RNAi therapeutic, in development for the treatment of transthyretin amyloidosis (#ATTR). See the findings: https://bit.ly/3UVskGi #RNAiTherapeutics

We’re thrilled to connect with thousands of cardiology professionals at the American Heart Association Scientific Sessions 2024 (#AHA24) this week in Chicago. Visit us at Booth 2321 to learn more about our recent innovations in #ATTR #amyloidosis, ATTR-CM and #hypertension #RNAiTherapeutics